Diadema Partners’s Arcus Biosciences RCUS Stock Holding History

Diadema Partners’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.82M	Buy	+124,000	New	+$3.06M	0.48%	52

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Diadema Partners's RCUS Position: Q2 2026 in Review

Diadema Partners reduced its Arcus Biosciences (RCUS) stake by 6% in Q2 2026, selling an estimated $354K and leaving 223,810 shares worth $6.9M. The position accounts for 0.87% of the portfolio, ranked #35.

Diadema Partners first reported a position in RCUS in Q4 2024 and has held it in 3 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Diadema Partners held 223,810 shares of Arcus Biosciences worth $6.9M as of Q2 2026.
Diadema Partners sold 14,332 Arcus Biosciences shares in Q2 2026, an estimated $354K.
Arcus Biosciences made up 0.87% of Diadema Partners's portfolio in Q2 2026, its #35 holding.
Diadema Partners first reported a position in Arcus Biosciences in Q4 2024 and has held it in 3 quarters since.
232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.